1.
Kanjilal S, Sater MRA, Thayer M, et al. Trends in Antibiotic Susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014. J Clin Microbiol. 2018;56(1). doi:10.1128/JCM.01160-17.
1.
Cheng S-C, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684. doi:10.1126/science.1250684.
1.
Calderwood MS, Desjardins CA, Sakoulas G, et al. Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus. J Infect Dis. 2014;209(4):571-7. doi:10.1093/infdis/jit501.
1.
McAdam PR, Templeton KE, Edwards GF, et al. Molecular tracing of the emergence, adaptation, and transmission of hospital-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2012;109(23):9107-12. doi:10.1073/pnas.1202869109.
1.
Kos VN, Desjardins CA, Griggs A, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio. 2012;3(3). doi:10.1128/mBio.00112-12.
1.
Cameron DR, Ward DV, Kostoulias X, et al. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis. 2012;205(11):1677-87. doi:10.1093/infdis/jis252.
1.
Peleg AY, Miyakis S, Ward DV, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One. 2012;7(1):e28316. doi:10.1371/journal.pone.0028316.
1.
Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827. doi:10.1038/srep11827.
1.
Reck F, Alm R, Brassil P, et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J Med Chem. 2011;54(22):7834-47. doi:10.1021/jm2008826.